–  ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated –  ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen –  Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk CARLSBAD, Calif., April 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. […]